The Right to Be Forgotten: A New Era of Dignity for Cancer Survivors

Life after cancer should not be accompanied by lifelong financial exclusion

For many decades, completing cancer treatment did not always mean the end of obstacles for those who had been diagnosed with the disease. Years after their treatment, many survivors continued to face higher insurance premiums, denied insurance applications, and difficulties accessing financial services.A history of cancer could act as a permanent “stigma,” even many years after treatment had ended.

Thus, medical progress and a return to daily life were not always accompanied by corresponding social and economic rehabilitation.

With Law No. 5317/2026, published on July 10, 2026, Greece is moving forward with the legislative enshrinement of the so-called “Right to Be Forgotten” for cancer survivors, in the context of insurance contracts linked to consumer credit agreements. This specific provision is found in Article 16, paragraph 4, of the law.

What the new provision stipulates

The law prohibits the use of personal data related to a consumer’s cancer diagnosis when such data is to be used for an insurance contract linked to a credit agreement and five years have passed since the completion of treatment.

Simply put, once the five-year period has elapsed, a prior history of a cancer diagnosis cannot be used in this specific context as a factor in assessing the insurance contract accompanying the credit agreement. This represents a significant shift: individuals are no longer assessed indefinitely through the lens of a past
illness, but are given the opportunity to move forward with their lives without their previous diagnosis serving as a permanent obstacle.

The four key points of the new entitlement

The Right to be Forgotten does not mean that the diagnosis is deleted from the medical record. It means that, after the prescribed five-year period, data related to the cancer diagnosis may not be used for that specific insurance purpose.

Fourth, special oversight is provided for.

The Personal Data Protection Authority is responsible for enforcing paragraph 4 of Article 16 and possesses the supervisory and auditing powers provided for by the General Data Protection Regulation.

What the New Regulation Does Not Cover

Accurate information is particularly important so that citizens are aware of both their rights and the actual
limits of the protection provided.

The new legislative provision:

  • does not apply to all forms of private insurance,
  • does not automatically guarantee the approval of a loan or an insurance application,
  • does not cover credit agreements secured by a mortgage on real property,
  • does not cover credit intended for the purchase or retention of rights in real estate,

does not cover professional or business loans, as the law applies to consumers acting outside the
scope of their professional or business activities.

Furthermore, consumer credit agreements already in effect as of November 20, 2026, will, as a general rule, continue to be governed by the previous legal framework until their expiration.
Therefore, the new regulation represents a very important step, but it does not yet provide comprehensive coverage of all the financial and insurance needs of survivors.

From Voluntary Commitment to Legal Enshrinement

The Right to Be Forgotten did not first appear in Greece in 2026. As of March 26, 2024, the Code of Ethics of the Hellenic Association of Insurance Companies has been in effect, to which life insurance companies had adhered.

The Code applied to life insurance policies linked to mortgage, business, or consumer loans, with a maximum total insured amount of 300,000 euros. It provided for a ten-year period following the completion of treatment for those diagnosed as adults and a five-year period for those diagnosed before
turning 18.

The new legislation is particularly significant because protection is no longer based exclusively on the insurance industry’s voluntary commitment. For contracts falling within its scope, the failure to use the oncological diagnosis after the five-year period becomes a legal obligation.

At the same time, there is a need to clarify the relationship between the new law and the existing Code, particularly with regard to mortgage and business loans that are not subject to the new legislative provision.

Additional Safeguards for Consumers

Article 16 includes other important safeguards. When insurance is required for the granting of credit, the creditor must accept equivalent insurance coverage from an insurance company of the consumer’s choice. Choosing a different company must not result in less favorable credit terms.

At the same time, the consumer is given a period of at least three business days to compare insurance quotes, unless the consumer requests in writing that the contract be concluded earlier.

The European Dimension

The Greek regulation transposes Directive (EU) 2023/2225 on consumer credit agreements. The European
Directive requires Member States to establish a time limit beyond which data related to oncological
diagnoses may not be used for insurance policies linked to credit agreements. The European text stipulated that this period must not exceed fifteen years; Greece opted for the significantly shorter period of five years.

This choice has particular social significance. It recognizes that advances in oncology, increased survival rates, and people’s return to family, social, and professional life must be accompanied by corresponding
developments in the law.

When Does It Take Ef ect?

Although Law No. 5317/2026 has already been published, the provisions of Part A, which include the
Right to Be Forgotten, will take effect on November 20, 2026.
Until then, substantial preparation is required on the part of banks, insurance companies, and the relevant
authorities. Clear procedures, understandable information for citizens, appropriate staff training, and an
easily accessible mechanism for submitting reports or complaints are needed.

A Significant Achievement—Not the End of the Journey

The Right to Be Forgotten represents a significant institutional victory for dignity and equality. Cancer
should not be a lifelong social and economic stigma. A person’s medical history should not negate their
right to plan for the future, participate equally in society, and make a fresh start.
At the same time, the new regulation must be viewed as a starting point, not the culmination of our
efforts. The next step must be to extend meaningful protection to more insurance and financial products,
including housing needs, as well as to address the discrimination that continues to occur in the workplace
and other aspects of social life.
Scientific progress has transformed cancer from a terminal diagnosis into an experience of life and
survival for millions of people. Society and the law must follow suit.

Because the Right to Be Forgotten is not a privilege. It is every person’s right not to remain forever
trapped by a past diagnosis—and to move forward into the future without discrimination, without
stigma, and with dignity.

Find more : http://elib.aade.gr/elib/view?

Mapping the efficiency of cancer care in Greece: findings from the All.Can Greece report

Cancer care efficiency in Greece remains one of the most complex and pressing challenges for the Greek health system — not only in terms of its clinical burden, but also in how care is organized around the patient.

With approximately 63,000 new cancer cases diagnosed annually and more than 32,000 cancer-related deaths each year, Greece faces a steadily increasing oncological burden. Projections suggest that cancer incidence will rise by around 23% by 2040, further intensifying pressure on health services.

Against this backdrop, All.Can Greece has published a landmark report titled “Mapping the Efficiency of Cancer Care in Greece”, based on the pilot implementation of the All.Can Action Guide for Efficient Cancer Care.

Rather than simply describing the current situation, the report aims to measure it — identifying where efficiency is lost across the cancer care pathway and where targeted reforms could make the greatest impact.

Cancer care efficiency in Greece: delays in care delivery

One of the most critical findings of the report relates to delays in the patient journey.

Despite the existence of modern infrastructure and highly specialized oncology centres, significant delays persist between initial suspicion, diagnosis, and the start of treatment.

These delays are not the result of a single bottleneck, but of systemic fragmentation:

  • fragmented referral pathways,
  • limited coordination between levels of care,
  • and the absence of standardized clinical protocols.

A key structural weakness is the lack of systematic monitoring of waiting times and time-to-treatment indicators. As a result, inefficiencies remain partially invisible to the system itself, limiting the ability to implement targeted improvements.

Fragmentation across the care continuum

The report highlights a broader issue of fragmentation in cancer care delivery.

The patient journey from primary care to specialist oncology services is often not clearly structured or consistently coordinated. Referral pathways depend heavily on individual practice rather than standardized national protocols.

A major gap is the absence of structured patient navigation services. In practice, this means that patients and families are often left to navigate a complex system on their own, increasing delays and adding unnecessary psychological burden.

At the same time, multidisciplinary tumor boards represent a positive development, supporting collaborative clinical decision-making across specialties. However, systematic monitoring of their performance remains limited.

The development of Comprehensive Cancer Centers is identified as a promising step forward, although further regulatory strengthening and clearer governance structures are still needed to maximize their impact.

Patient-centered care: progress with remaining gaps

Greece has made notable progress in collecting Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs), reflecting a growing commitment to integrating patient perspectives into care delivery.

However, patients’ access to their own clinical data remains limited, restricting their ability to actively participate in decision-making processes.

In addition, patient education and shared decision-making are not yet systematically embedded across the health system.

Another important gap concerns survivorship care. As cancer survival rates improve, the lack of structured long-term follow-up pathways leaves many patients without continuous support after active treatment ends.

Key policy directions

The report outlines several strategic priorities for improving cancer care efficiency in Greece:

  • Development of a comprehensive national cancer strategy with clear targets and governance mechanisms
  • Strengthening coordination across all levels of care
  • Implementation of standardized clinical pathways with defined time-to-treatment and quality indicators
  • Investment in oncology workforce capacity, particularly in shortage specialties
  • Establishment of structured patient navigation programmes
  • Acceleration of Comprehensive Cancer Center development
  • Systematic use of health data for monitoring performance and accountability
  • Greater patient engagement through PROMs, PREMs, and shared decision-making

Conclusion: a system with strong foundations but limited integration

Greece has many of the essential building blocks for a high-performing cancer care system — including infrastructure, clinical expertise, and emerging digital health capabilities.

However, the key challenge lies not in the existence of these components, but in their integration.

The All.Can Greece report highlights a system that is still operating in silos: strong individual elements that do not yet function as a fully connected care pathway.

In oncology, this lack of integration is not merely an organizational issue. It directly affects timeliness, patient experience, and ultimately outcomes.

The opportunity now lies in moving from fragmented capacity to coordinated care — where patients no longer have to bridge the gaps between system components themselves.

Source: Mapping-the-Efficiency-of-Cancer-Care-in-Greece-FINAL

Text/adaptation: Ifiyenia Anastasiou for Kapa3

Continuing the Journey: Online Group Sessions for Mental Health and Nutrition – Third Cycle with Kapa3 and the LB.H.Sc

Following the warm response to the second cycle of meetings (see the related article here ), focusing on Nutritional Guidance and Experiential Psychological Support, Kapa3 and the Laboratory of Basic Health Sciences (LB.H.Sc), Department of Nursing University of Peloponnese are delighted to continue their collaboration with a third series of online group sessions for mental health and nutrition, dedicated to the holistic care of body and mind, designed for people living with cancer and their caregivers.

In this third cycle, mental health and nutrition are approached as two complementary sides of the same care.

The mental health sessions help participants recognize and manage challenging emotions such as anxiety, fear, sadness, or guilt, strengthen resilience, and cultivate a deeper connection with themselves and others.

The nutrition sessions explore how mindful and balanced eating can support the body, improve energy and mood, and become a meaningful act of self-care. Food is not only a necessity but also a way to nurture the body, mind, and spirit.

Program of Online Sessions for Mental Health and Nutrition & Themes

  • Saturday, February 28, 2026, 17:30–19:00
    Myths and truths about “anti-cancer” diets. How to evaluate nutritional information and avoid risky practices.

  • Saturday, March 14, 2026, 17:30–19:00
    Stress and uncertainty: practical ways to manage them during treatments and exams.

  • Saturday, March 21, 2026, 17:30–19:00
    Giving space to emotions without being overwhelmed: recognizing and expressing fear, anger, sadness, and guilt.

  • Saturday, March 28, 2026, 17:30–19:00
    Nutritional support during treatment & the role of cachexia.

  • Saturday, April 25, 2026, 17:30–19:00
    Boundaries without guilt: protecting energy and mental resilience.

  • Saturday, May 9, 2026, 17:30–19:00
    Safe cooking practices & kitchen hygiene.

  • Saturday, May 23, 2026, 17:30–19:00
    Family and illness: changes in relationships and ways to support each other.

  • Saturday, June 6, 2026, 17:30–19:00
    The Tree of Life: who I am beyond the illness.

  • Saturday, June 13, 2026, 17:30–19:00
    What gives meaning to life now: discovering small but meaningful elements that sustain us.

Format & Participation

The meetings are held online, based on dialogue, experiential learning, and the sharing of personal experiences. Everyone participates at their own pace, in a warm environment of acceptance and trust. Consistent attendance helps build safety and confidence within the group.

To express your interest or join the first session of the third cycle (Saturday, February 28, 17:30–19:00): [Registration Link]

Text/adaptation: Ifiyenia Anastasiou for Kapa3

GD2: A Critical Biomarker and Therapeutic Target – What the Latest Evidence Shows

New scientific data highlight GD2 — a glycolipid biomarker expressed in specific cancer cells — as one of the most promising therapeutic targets in modern oncology. A recent review published in an international scientific journal brings together the latest findings on the use of GD2 in immunotherapies, CAR-T cell treatments, monoclonal antibodies, and other innovative approaches.

What is GD2 and why does it matter?

GD2 is a molecule known as disialoganglioside-2, found in high concentrations on the surface of certain cancer cells. This makes it particularly valuable as a target for personalized immunotherapies, as treatments can “recognize” and destroy GD2-positive cells while sparing healthy tissues.

Cancers with high GD2 expression include:
• Neuroblastoma
• Osteosarcoma
• Melanoma
• Breast cancer (triple-negative in some cases)
• Certain lung cancers
• Rare pediatric tumors

In neuroblastoma — one of the most common pediatric cancers — GD2-directed antibody therapy has already improved survival in high-risk patients.

The new scientific review maps the current progress in GD2-targeted therapies, highlighting the technologies showing the strongest clinical potential. GD2-directed monoclonal antibodies, already effective in children with neuroblastoma, are evolving into more precise and safer versions, aiming to expand their use in adult tumors as well. The review also presents updated data from clinical trials of GD2-directed CAR-T cells: despite challenges such as toxicity, tumor escape, and limited persistence, newer CAR-T generations demonstrate improved safety, deeper penetration into solid tumors, and especially promising outcomes in pediatric patients.

The review further examines combination immunotherapies that pair GD2 targeting with radiotherapy, chemotherapy, or immune checkpoint inhibitors, offering enhanced effectiveness against resistant tumors. Finally, emerging platforms are described — including bispecific antibodies, “smart” nanoparticle-based strategies, and drug-delivery technologies that target only GD2-positive cells — expanding the therapeutic landscape and opening new avenues for future applications.

What does this mean for patients?

GD2-targeted therapy is no longer theoretical — it is already a reality in certain pediatric cancers and is rapidly expanding into other tumor types.

Key benefits for patients include:
• greater precision with reduced toxicity
• the potential for highly individualized treatment based on tumor profile
• new hope for tumors that remain difficult to treat with existing methods
• improved survival prospects, especially for children

For pediatric and young adult patients — a group with historically limited and often highly burdensome treatment options — GD2-directed therapies represent a significant step forward.

Despite the important progress made, several challenges remain. These include side effects such as neuropathic pain, tumor resistance or escape from targeting, the high cost and limited availability of advanced treatments, and the need for large, multi-center clinical trials to produce more robust and generalizable data. Still, research activity is intensifying, with dozens of clinical studies currently ongoing worldwide.

Within this evolving landscape, Kapa3 remains committed to providing accurate, accessible, and compassionate information to patients and families, particularly those facing severe, rare, or pediatric cancers. Advances in GD2-targeted therapies are opening new pathways for children and young people with limited options today , showcasing the power and potential of immunotherapy. At the same time, they highlight the urgent need for equitable access to innovative treatments for patients in Greece.

Kapa3 will continue to follow scientific developments closely and keep the community informed in a clear, reliable, and human-centered way.

Sources: Here

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

Biomarkers Open New Paths in Cancer Treatment in Greece

Good news for cancer patients in Greece — access to personalized treatments is now becoming a reality.

A recent decision by the Ministry of Health (ΦΕΚ Β’ 5627/20-10-2025, Απόφαση Δ3(α) 41081/2025) approves and reimburses a wider range of biomarker tests, marking an important step forward for modern oncology care.

Read the Government Gazette here

But what are biomarkers?
They are special indicators detected through molecular tests that help doctors understand the unique characteristics of each patient’s cancer. In simple terms, biomarkers act like a “compass,” guiding doctors to choose the most effective and safest treatment for every individual.

Until now, only a few biomarkers were covered by the public health system — for example, molecular signatures that determine whether a woman with early-stage breast cancer needs chemotherapy (approved in 2018), or BRCA1/2 gene tests that reveal inherited risk for breast and ovarian cancer.

The new decision significantly expands this list, adding additional biomarkers for 39 indications. This allows oncologists to tailor treatments to the specific profile of each patient’s tumor, bringing Greece closer to international standards of personalized medicine.

KAPA3, which consistently supports patient education and empowerment, welcomes this development as a vital step toward more human-centred, targeted care.

This progress brings hope, better quality of life, and greater trust in the healthcare system. It is only the beginning, but it lays strong foundations for a future where every patient has access to the right treatment, at the right time.

Learn about patient rights via KAPA3’s extensive library here

Learn more about cancer biomarkers here

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

Kapa3 at the Patients Summit 2025: A strong voice for cancer patients and their families

The Patients Summit 2025—the annual nationwide meeting organized by the Hellenic Patients Association—was successfully completed with great success. The event has become the leading forum for dialogue and collaboration among patient organizations across Greece. This year’s conference brought together representatives of patient associations, healthcare professionals, and policymakers to strengthen the voice of patients and shape a more humane, participatory, and effective healthcare system.

Participants exchanged experiences, presented best practices, and discussed key issues such as sustainability of patient associations, access to innovative treatments, the use of digital health tools, and patient empowerment in decision-making.

Through thematic panels and interactive workshops, the event highlighted the need for cooperation, transparency, and the use of data to drive targeted solutions with real social impact.

Kapa3 actively participated in the Summit, representing cancer patients and their families. A highlight of its presence was its contribution to the Strategic Workshop: “How do we measure our value?”, where Kapa3 presented its approach and operational philosophy on data collection and utilization as a tool for developing innovative initiatives.

For Kapa3, data collection is a key process in understanding the real needs of its beneficiaries. As emphasized during the session, data analysis—conducted in collaboration with the organization’s biostatistician, Mr. Konstantinos Tzanas—helps Kapa3 design targeted and evidence-based strategies. Continuous evaluation by patients themselves enables the adaptation of services and the development of innovative solutions that have a tangible, positive impact on their lives.

Kapa3’s presence at the Patients Summit 2025 underscored the importance of collaboration, scientific evidence, and collective action. The organization remains committed to amplifying the voice of cancer patients through knowledge, innovation, and transparency—values that can truly transform the patient experience and contribute to a fairer, more humane healthcare system for all.

 

Continuing the Journey: Holistic Body and Mind Care with Kapa3 and the University of the Peloponnese

After the first round of meetings held in April (see the related article here), focusing on Nutritional Guidance and Experiential Psychological Support, Kapa3 and the University of the Peloponnese continue their collaboration with a new series of experiential workshops dedicated to the holistic care of body and mind.

The meetings are open to people living with cancer, caregivers, and healthcare professionals — to anyone seeking a space for genuine communication, understanding, and empowerment.

In this new cycle, mental health and nutrition are approached as two sides of the same care.

In the mental health sessions, participants learn to recognize and manage challenging emotions such as anxiety or fear, strengthen their resilience, and cultivate a deeper connection with themselves and others.

At the same time, the nutrition sessions explore how balanced and mindful eating can support the body, enhance energy and mood, and become an act of self-care and self-respect. Food is not only a necessity but also a way to show love — to the body, the soul, and to life itself.

The meetings are held online and are based on dialogue, experiential learning, and the sharing of personal experiences. Everyone participates at their own pace, in a warm environment of acceptance and trust.

To express your interest: Registration Form for the Support Group for People with Cancer

Text/adaptation: Ifiyenia for Kapa3

ESMO Highlights the Importance of Prioritising the Fight Against Cancer in the EU4Health 2026 Work Programme

The European Society for Medical Oncology (ESMO) submitted its response to the public consultation on the 2026 Annual Work Programme of EU4Health, emphasising the urgent need to make cancer a top priority across Europe. With the number of cancer cases projected to rise from over 4.47 million in 2022 to 5.48 million in 2045, ESMO calls for dedicated EU4Health actions to address this growing challenge.

Among the key areas highlighted by ESMO is the importance of improving accessibility to healthcare based on current medical knowledge and international standards, while adequately monitoring the quality of healthcare services to prevent inequalities across the EU. This approach aligns closely with the mission and activities of Kapa3, which aims to ensure equitable access to health support for all, particularly young adults affected by cancer.

Through its initiatives, Kapa3 actively promotes awareness, supports access to quality healthcare, and works to reduce disparities in health services, reflecting the same commitment emphasised by ESMO in its response to EU4Health.

Read more on ESMO’s response, here